Mycosis fungoides;Mycosis fongoide

Annales de Dermatologie et de Venereologie

Volumn 124, Issue 1, 1997, Pages 69-90

  Richard Lallemand, M A ^a   Carsuzaa, F ^b  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b Service de Dermatologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1 PROPENYL]BENZOIC ACID ETHYL ESTER; ACICLOVIR; ALPHA INTERFERON; BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; ETOPOSIDE; ETRETINATE; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 2; ISOTRETINOIN; METHOTREXATE; METHOXSALEN; PREDNISONE; RETINOID; THYMOCYTE ANTIBODY; THYMOPENTIN; VINCRISTINE; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT;

CLINICAL TRIAL; DEPRESSION; HUMAN; LIVER TOXICITY; MYCOSIS FUNGOIDES; PHOTOTHERAPY; PHOTOTOXICITY; PUVA; REVIEW; SKIN TOXICITY; ULTRAVIOLET B RADIATION; CANCER STAGING; DRUG COMBINATION; MORTALITY; PATHOLOGY; SKIN TUMOR; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARMUSTINE; DRUG THERAPY, COMBINATION; HUMANS; MECHLORETHAMINE; MYCOSIS FUNGOIDES; NEOPLASM STAGING; PHOTOTHERAPY; RETINOIDS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031300448     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (192)

1. Harris NL., Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-Americain classification of lymphoid neoplasms. A proposal from the international lymphoma study group. Blood 1994;84:1361-92.
2. Wieselthier JS, Koh HK. Sézary syndrome: diagnosis, prognosis, and critical review of treatment options, J Am Acad Dermatol 1990;22:381-401.
3. Hoppe RT, Wood GS, Abel EA. Mycosis fungoides and the Sézary syndrome: pathology, staging and treatment. Curr Probl Cancer 1990;14:299-361.
4. Jones CW. Mycosis fungoides: issues and management in 1995. Cancer Journal 1994;7:214-9.
5. Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 1995;131:1003-8.
6. Sausville EA, Eddy JL, Makuch RW, Fischmann AB, Schechter GP, Matthews M, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Ann Intern Med 1988;109:372-82.
7. Kemme DJ, Bunn PA. State of the art therapy of mycosis fungoides and Sezary syndrome. Oncology 1992;6:31-42.
8. Abel EA, Wood GS, Hoppe RT. Mycosis fungoides: clinical and histologic features, staging, evaluation, and approach to treatment. Cancer J Clin 1993;43:93-115.
9. Weinstock MA. Epidemiology of mycosis fungoides. Semin Dermatol 1994;13:154-9.
10. Lorincz AL. Cutaneous T-cell lymphoma (mycosis fungoides). Lancet 1996;347:871-6.
11. Collet JP, Salmi LR. Lecture critique des articles médicaux. V: Juger de l'intérêt d'une nouvelle thérapeutique. Rev Prat 1992;42:335-9.
12. Poynard T. Evaluation de la qualité méthodologique des essais thérapeutiques. Presse Med. 1988;17:315-8.
13. Kaye FJ, Bunn PA, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, et al. A randomized trial comparing combination electron - beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Eng J Med 1989;321:1784-90.
14. Broder S, Bunn PA. Cutaneous T-cell lymphomas. Semin Oncol 1980;7:310-31.
15. Bunn PA, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy for cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 1994;121:592-602.
16. Holloway KB, Flowers FP, Ramos-Caro FA. Therapeutic alternatives in cutaneous T cell lymphoma. J Am Acad Dermatol 1992;27:367-78.
17. Jörg B, Kerl H, Thiers BH, Bröcker EB, Burg G. Therapeutic approaches in cutaneous lymphoma. Dermalol Clin 1994;12:433-41.
18. Simoni R, Cavalieri R, Coppola G, Ricciotti L, De Pita O, Criscuolo D, et al. Recombinant leukocyte Interferon alfa-2a in the treatment of mycosis fungoides. J Biol Regul Homeost Agents 1987;1:93-9.
19. Vegna ML, Papa G, Defazio D, Pisani F, Coppola G, De Pita O, et al. Interferon alpha 2-a in cutaneous T-cell lymphoma. Eur J Haematol 1990;45(suppl 12):32-5.
20. Papa G, Tura S, Mandelli F, Vegna ML, Delazio D, Mazza P, et al. Is Interferon alpha in cutaneous T-cell lymphoma a treatment of choice ? Br J Haematol 1991;79(suppl I):48-51.
21. Jones GW, Tadros A, Hodson DI, Rosenthal D, Roberts J, Thorson B. Prognosis with newly diagnosed mycosis fungoïde after total skin electron radiation of 30 or 35 Gy. Int J Radiat Oncol Biol Phys 1994;28:839-45.
22. Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 1987;123:201-4.
23. Gilchrest BA, Parrish JA, Tanenbaum L. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 1976;38:683-9.
24. Gilchrest BA. Methoxsalen photochemotherapy for mycosis fungoides. Arch Dermatol 1979;115:50-3.
25. Roenig HH Jr. Photochemotherapy for mycosis fungoides. Arch Dermatol 1977;113:1047-51.
26. Gilchrest BA. Methoxsalen photochemotherapy for mycosis fungoides. Cancer Treat Rep 1979;63:663-7.
27. Gasparro FP, Dall'amico R, O'Malley M. Cell membrane DNA: a new target for psoralen photoadduct formation. Photochem Photobiol 1990;52:315-21.
28. Mostow EN, Neckel SL, Oberhelman L, Anderson TF, Cooper KD. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined Interferon alfa and PUVA. J Am Acad Dermatol 1993;129:747-52.
29. Molin L, Thomsen K, Volden G, Grolh O. Photochemotherapy (PUVA) in the pretumour stage of mycosis fungoïdes: a report from the Scandinavian mycosis fungoïdes study group. Acta Derm Venereol (Stockh) 1980;61:47-51.
30. Hönigsmann H, Brenner W, Rauschmeier W, Konrad K, Wolff R. Photochemotherapy for cutaneous T cell lymphoma. A follow up study. J Am Acad Dermatol 1984;10:238-45.
31. Abel EA, Sendagorta E, Hoppe RT, Hu CH. PUVA Treatment of erythrodermic and plaque type Mycosis fungoides. Ten years follow-up study. Arch Dermatol 1987;123:897-901.
32. Hermann JJ, Roenig HH, Hurria A, Kuzel TM, Samuelson E, Rademaker AW, et al. Treaiment of mycosis fungoïdes with photochemotherapy (PUVA): Long-term follow-up. J Am Acad Dermatol 1995;33:234-42.
33. Molin L, Thomsen K, Volden G, Groth O. Photochemotherapy (PUVA): in the tumour stage of mycosis fungoïdes: a report from the Scandinavian mycosis fungoides study group. Acta Derma Venereol (Stockh) 1981;61:52-4.
34. Du Vivier A, Vollom DI. Photochemotherapy and topical nitrogen mustard in the treatment of mycosis fungoïdes. Br J Dermatol 1980;102:319-22.
35. Abel EA, Sendagorta E, Hoppe RT. Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoïdes. J Am Acad Dermatol 1986;14:1029-38.
36. Smoller BR, Marcus R. Risk of secondary cutaneous malignancies in patients with long standing mycosis fungoïdes. J Am Acad Dermatol 1994;30:201-4.
37. Licata AG, Wilson LD, Braverman IM, Feldman AM, Kacinski BM. Malignant melanoma and other second cutaneous malignancies in cutaneous T cell lymphoma. The influence of additional therapy after total skin electron beam radiation. Arch Dermatol 1995;131:432-5.
38. Reseghetti A, Tribbia G, Locati F, Marchesi L. Cutaneous malignant melanoma appearing during photochemotherapy of mycosis fungoïdes. Dermatology 1994;189:75-7.
39. Wolf P, Cerroni L, Smolle J, Kerl L. PUVA induced lymphomatoid papulosis in a patient with mycosis fungoïdes. J Am Acad Dermatol 1991;25:422-6.
40. Swanbeck G, Roupe G, Sandstrom MH. Indications of a considerable decrease in death rate in mycosis fungoïdes by PUVA treatment. Acta Derm Venereol (Stockh) 1994;74:465-6.
41. Nakamura M, Kobayashi S, Matsubara K, Tawaka T, Furukawa F, Imamura S. The effects of non interval PUVAtherapy on the plaque stage of mycosis fungoïdes. J Dermatol 1995;22:196-200.
42. Thomsen K, Hammar H, Molin L, Volden G. Retinoides plus PUVA (Re PUVA) and PUVA in mycosis fungoïdes plaque stage. Acta Derm Venereol (Stockh) 1989;69:536-8.
43. Ramsay DL, Lishk M, Yalowitz CB, Soter NA. Ultraviolet-B phototherapy for early stage of cutaneous T Cell lymphoma. Arch Dermatol 1992;128:931-3.
44. Resnick KS, Vonderheid EC. Home UV phototherapy of early mycosis fungoïdes. Long term follow-up observations in thirty-one patients. J Am Acad Dermatol 1993;29:73-7.
45. Zackeim HS. Treatment of cutaneous T cell lymphoma. Semin Dermatol 1994;13:207-15.
46. Trump JG, Wright KA, Evans WW, Anson JH, Hare HF, Fromer J, et al. High energy electrons for the treatment of extensive superficiel malignant lesions. Am J Roentgenol 1953;69:623-9.
47. Hoppe RT, Cox RS, Fuks Z, Price NM, Bagshaw MA, Farber EM. Electron beam therapy for mycosis fungoïdes. Cancer Treat Rep 1979;691-700.
48. Kuten A, Rosenblatt E, Dale J, Leviov M, Tatcher M. Total skin electron irradiation: efficacy in early mycosis fungoides. Leuk Lymph 1993;10:281-5.
49. Hoppe RT, Fuks Z, Bagshaw MA. Radiation therapy in the management of cutaneous T cell lymphoma. Cancer Treat Rep 1979;63:625-32.
50. Wilson LD, Cooper DL, Goodrich AL. Impact on non - CTCL dermatologic diagnosis and adjuvant therapies on cutaneous T cell lymphomas patients treated with total skin electron beam radiation therapy. Int J Radiat Oncol Biol Phys 1994;28:829-37.
51. Price NM, Hoppe RT, Constantine VS, Fuks ZY, Farber EM. The treatment of mycosis fungoïdes: adjuvant topical mechorethamine after electron beam therapy. Cancer 1977;40:2851-3.
52. Kuten A, Stein M, Mandelzweig Y, Tatcher M, Yaacou G, Epelbaum R, et al. Total skin electron irradiation for cutaneous T cell lymphoma: the northerm Israel Oncology Center Expérience. Strahlenter Onkol 1991;167:392-6.
53. Maingon P, Horiot JC, Lambert D, Duong M, Bone MC, Naudy S. Radiotherapy of mycosis fungoïdes. (Abstract 331). Radiother and Oncol 1992;24:S84.
54. Hoppe R. The management of mycosis fungoïdes at Stanford - Standard and innovative treatment programmes. Leukemia 1991;5(suppl. I):46-8.
55. Tadros AAM, Tepperman BS, Hryniuk WM, Peters VG, Rosenthal D, Roberts JT. Total skin electron beam therapy for mycosis fungoïdes: failure analysis and prognostic factors. Int J Radiat Oncol Biol Phys 1983;9:1279-87.
56. Van Vloten WA, De Vroome H, Noordjik EM. Total skin electron beam irradiation for cutaneous T cell lymphoma (mycosis fungoïdes). Br J Dermatol 1985;112:697-702.
57. Le Bourgeois JP, Levy E, Haddad E, Marinello G, Geara F, Pavlovitch JM. Electronthérapie cutanée totale du mycosis fongoïde. Ann Dermatol Vénéréol 1989;116:213-7.
58. Micaily B, Moser C, Vonderheid EC, Koprowski C, Lightfoot D, Markoe A, et al. The radiation therapy of early stage cutaneous T cell lymphoma. Int J Radiat Oncol Biol Phys 1990;18:1333-9.
59. Reddy S, Parker CM, Shidnia H, Gaffney MG, Blyton BD, Pruner LM, et al. Total skin electron beam radiation therapy for mycosis fungoïdes. Am J Clin Oncol 1992;15:119-24.
60. Wilson LD, Licata AL, Bravermann IM, Edelson RL, Heald PW, Feldman AM, et al. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radial Oncol Biol Phys 1995;32:987-95.
61. Becker M, Hoppe RT, Knox SJ. Multiple courses of high dose total skin electron beam therapy in the management of mycosis fungoïdes. Int J Radiat Oncol Biol Phys 1995;32:1445-9.
62. Winkelmann RK, Diaz-Perez JL, Buechner SA. The treatment of Sezary syndrome. J Am Acad Dermatol 1984;10:1000-4.
63. Desai KR, Pezner RD, Lipsett JA, Vora NL, Luk KH, Wong JYC, et al. Total skin electron irradiation for mycosis fungoïdes: relationship between acute toxicities and measured dose at different anatomic sites. Int J Radiat Oncol Biol Phys 1988;15:641-5.
64. Hoppe RT, Abel EA, Deneau DG, Price NM. Mycosis fungoïdes: management with topical nitrogen mustard. J Clin Oncol 1987;5:1796-1803.
65. Jones G, Mc Lean J, Rosenthal D. Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T cell lymphoma (mycosis fungoïdes and Sezary Syndrome). J Am Acad Dermatol 1992;26:960-7.
66. Winkler CF, Sausville EA, Ihde DC, Fischmann AB, Schechter GP, Kumar PP, et al. Combined modality treatment of cutaneous T cell lymphoma. Results of a 6 years follow-up. J Clin Oncol 1986;4:1094-100.
67. Hallahan DE, Griem ML, Griem SF, Medenica M, Soltani K., Lorincz AL, et al. Combined modality therapy for tumor stage mycosis fungoïdes: results of a 10 years follow-up. J Clin Oncol 1988;6:1177-83.
68. Lambert D, Bousser AM, Dalac S, Godard W, Lepinoy D, Horiot JC. Mycosis fungoïde et radiothérapie. Intérêt de l'association: électronthérapie superficielle totale et photonthérapie corporelle globale. Ann Dermatol Vénéréol 1986;113:541-7.
69. Halberg FE, Fuk K, Weaver KA, Zackeim HS, Epstein EH, Wintroub BU. Combined total body X-ray irradiation and total skin electron beam radiotherapy with an improved technique for mycosis fungoïdes. Int J Radiat Oncol Biol Phys 1989;17:427-32.
70. Micaily B, Campbell O, Moser C. Total skin electron beam and total nodal irradiation of cutaneous T cell lymphoma. Int J Radiat Oncol Biol Phys 1991;20:809-13.
71. El-Khatib E, Hussein S, Nicolic M, Voss NJ, Parsons C. Variation of electron beam angulation and scatterer position for total skin irradiation with the Stanford technique. Int J Radial Oncol Biol Phys 1995;33: 469-74.
72. Hazerick J, Richardsen J, Grant D. Remission of lesions of mycosis fungoïdes following topical application of nitrogen mustard. A case report. Cleveland Clin 1959;26:44.
73. Ramsay DL, Halperin SL, Zelcniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoïdes. J Am Acad Dermatol 1988;19:684-91.
74. Vonderheid EC, Tan ET, Kantor AE, Sarrager L, Micaily B, Vanscott EJ. Long term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol 1989;20:416-28.
75. Hamminga B, Noordjik EM, Van Vloten WA. Treatment of mycosis fungoïdes. Total skin electron beam irradiation vs topical mechlorethamine therapy. Arch Dermatol 1982;118:150-3.
76. Zachariae H, Thestrup-Pedersen K, Sogaard H. Topical nitrogen mustard in early mycosis fungoïdes. A 12 year experience. Acta Derm Venereol (Stockh) 1985;65:53-8.
77. Zackeim HS, Epstein EH, Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15 years experience in 143 patients. J Am Acad Dermatol 1990;22:802-10.
78. Constantine VS, Fuks ZY, Farber EM. Mechlorethamine desensitization in therapy for mycosis fungoïdes: topical desensitization to mechlorethamine (nitrogen mustard) contact hypersensitivity. Arch Dermatol 1975;111:484-8.
79. Nielsen M, Rasmussen K, Knudsen N, Thestrup-Pedersen K. Long term topical nitrogen mustard treatment does not induce pulmonary librosis in MF patients. Acta Derm Venereol (Stockh) 1994;74:70-1.
80. Esteve E, Bagot M, Joly P, Souteyrand P., Souteyrand P, Beylot-Barry M, Vaillant L. Intolérance cutanée à la caryolysine: étude prospective de 50 malades. Ann Dermatol Vénéréol 1995;122 (suppl. 1):S36-S37.
81. Question du mois: Application à domicile de traitements topiques par une infirmière libérale. Ann Dermatol Vénéréol 1995;122:812-3.
82. Zackeim HS. Topical carmustine (BCNU) for patch plaque mycosis fungoïdes. Sem Dermatol 1994;13:202-6.
83. Mielke V, Staib G, Sterry W. Systemic treatment for cutaneous lymphomas. Recent Results Cancer Res 1995;139:403-8.
84. Travis LB, Curtis RE, Boice JD, Hankey BF, Fraumeni JF Jr. Second cancers following non - Hodgkin lymphoma. Cancer 1991;67:2002-9.
85. Kuzel TM, Roenigk HH, Rosen ST. Mycosis fungoides and the Sezary syndrome: a review of pathogenesis, diagnosis and therapy. J Clin Oncol 1991;9:1298-1313.
86. Zackheim HS, Epstein EH. Low-dose methotrexate for the Sezary syndrome. J. Am. Acad. Dermatol. 1989;21:757-62.
87. Zackheim HS, Kashani-Sabet M, Hwang ST. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 1996;34:626-31.
88. Mcdonald CJ, Bertino JR. Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor. Cancer Treat Rep 1978;62:1009-14.
89. Foss FM, Kuzel TM Experimental therapy in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1127-37.
90. Grever MR, Bisaccia E, Scarborough DA, Metz En, Neidhart JA. An investigation of 2′-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 1983;61:279-82.
91. Dang-Vu AP, Olsen EA, Vollmer RT, Greenberg ML, Hershfield MS. Treatment of cutaneous T-cell lymphoma with 2′-deoxycoformycin (pentostatin). J Am Acad Dermatol 1988;19:692-8.
92. Cummings FJ, Kim K, Neiman RS, Comis RL, Oken MM, Weitzman SA, et al. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 1991;9:565-71.
93. Dearden C., Matutes E, Catovsky D. Deoxycoformycin in the treatment of mature T-cell leukaemias. Br J Cancer 1991;64:903-6.
94. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. The role of pentostatin in the treatment of T-cell maligancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994;12:2588-93.
95. Von Hoff D, Dahlberg S, Hartstock R, Eyre HJ. Activity of fludarabine monophospate in patients with advanced mycosis fungoides. A Southwest Oncology Group Study. J Natl Cancer Inst 1990;82:1353-55.
96. O'Brien S, Kurzock R, Duvic M, Kantarjian H, Stass S, Robertson LE, et al. 2-Clorodeoxyadenosine therapy in with T-cell lymphoproliferative disorders. Blood 1994;84:733-8.
97. Suven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992;80:587-92.
98. Redman JR, Cabanillas F, Velasquez WS, Mclaughlin P, Hagemeister FB, Swan F, et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992;10:790-4.
99. Kantarjian HM, Redman JR, Keating MJ. Fludarabine phosphate therapy in other lymphoid malignancies. Sem Oncol 1990;17:66-70.
100. Rosen ST, Foss F. Chemotherapy for mycosis fungoides and the Sézary syndrome. Hematol Oncol Clin North Am 1995;9:1109-16.
101. Thomsen K. Scandinavian mycosis fungoides trial. Cancer Treat Rep 1979;63:709-11.
102. Molin L, Thomsen K, Volden G, Bergqvist-Karlsson A, Hallberg O, Hellbe L. Epipodophyllotoxin (VP-16-213) in mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Study Group. Acta Dermatol Venereol (Stockh) 1979;59:84-7.
103. Grozea PN, Jones SE, Mckelvey EM, Coltman CA, Fisher R, Haskins CL Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study. Cancer Treat Rep 1979;63:647-53.
104. Sentis HG, Willemze R, Van Vloten WA. Systemic polychemotherapy in patients with mycosis fungoides and lymph node involvement: a follow-up study of 17 patients. Acta Dermatol Venereol (Stockh) 1985;65:179-83.
105. Doberauer C, Ohl S. Advanced mycosis fungoides. Chemotherapy with etoposide, methotrexate, bleomycin and prednimustine. Acta Dermatol Venereol (Stockh) 1989;69:538-40.
106. Molin L, Thomsen K, Volden G, Groth O, Hellbe L, Holst R, et al. Combination chemotherapy in the tumor stage of mycosis fungoides with cyclophosphamide, vincristine. VP-16, adriamycin and prednisolone (COP, CHOP, CAVOP): a report from the Scandinavian Mycosis Fungoides Study Group. Acta Dermatol Venereol (Stockh.) 1980;60:542-4.
107. Case DC. Combination chemotherapy for mycosis fungoides with cyclophosphamide, vincrestine, methotrexate and prednisone. Am J Clin Oncol 1984;7:453-5.
108. Molin L, Thomsen K, Volden G, Jensen P, Knudsen E, Nyfors A, Schmidt H. Retinoids and systemic chemotherapy in cases of advanced mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Dermatol Venereol (Stockh) 1987;67:179-82.
109. Zachariea H, Grunnet E, Thestrup-Pedersen K, Molin L, Schmidt H, Starfelt F, Thomsen K. Oral retinoid in combination with bleomycin, cyclophosphamide, prednisone and transfer factor in mycosis fungoides. Acta Dermatol Venereol (Stockh) 1982;62:162-4.
110. Zachariea H, Thestrup-Pedersen K. Combination chemotherapy with bleomycin, cyclophosphamide, prednisone and etretinate (BCPE) in advanced mycosis fungoides: a six year experience. Acta Dermatol Venereol (Stockh) 1987;67:433-7.
111. Zakem MH, Davis BR, Adelstein DJ, Hines JD. Treatment of advanced stage mycosis fungoides with bleomycin, doxorubicin, and methotrexate with topical nitrogen mustard (BAM-M). Cancer 1986;58:2611-6.
112. Groth O, Molin L, Thomsen K. Tumor stage of mycosis fungoides treated with bleomycin and methotrexate: report from the Scandinavian Mycosis Fungoides Study Group. Acta Dermatol Venereol (Stockh) 1979;59:59-63.
113. Tirelli U, Carbone A, Veronesi A, Galligioni E, Trovo MG, Tumolo S, Grogoletto E. Combination chemotherapy with cyclophosphamide, vincristine, and prednisone (CVP) in TNM-classified stage IV mycosis fungoides. Cancer Treat Rep 1982;66:167-9.
114. Bigler RD, Crilley P, Micaily B, Brady LW, Topolsky D, Bulova S, et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 1991;7:133-7.
115. Koeppel MC, Stoppa AM, Resbeut M, Blaise D, Coignet M, Coulier L, et al. Mycosis fungoides and allogenic bone marrow transplantation. Acta Derm Vencreol (Stockh) 1994;74:331-2.
116. Sterling JC, Marcus R, Burrows NP, Roberts SOB. Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation. Clin Exp Dermatol 1995;20:73-5.
117. Zeitoun C, Baccard M, Marolleau JP, Rybojad M, Baruchel A, Morel P. Brice P. Autogreffe de moelle osseuse dans le traitement des lymphomes cutanés. Ann Dermatol Vénéréol 1996;123:79-84.
118. Dreno B. Roferon-A (Interferon Alpha 2a) combined with Tigason (Etretinate) for treatment of cutaneous T cell Lymphomas. Stem Cells 1993;11:269-75.
119. Hoting E, Meissner K. Arotinoid-ethylester. Effectiveness in refractory cutaneous T-cell lymphoma. Cancer 1988;62:1044-8.
120. Thomsen K, Molin L, Volden G, Wantzin GL, Hellbe L. 13-cis retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Dermatol Venereol (Stockh) 1984;64:563-6.
121. Molin L, Thomsen K, Volden G, Aronsson A, Hammur H, Hellbe L, et al. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and eretinate. Acta Dermatol Venereol (Stockh) 1987;67:232-6.
122. Claudy AL, Rouchouse B, Boucheron S, Le Petit JC. Treatment of cutaneous lymphoma with etretinate. Br J Dermatol 1983;109:49-56.
123. Dreno B, Celerier P, Litoux P. Roferon-A in combination with Tigason in cutaneous T-cell lymphomas. Acta Haematol 1993;89(suppl. I):28-32.
124. Dreno B, Claudy A, Meynadier J, Verret JL, Souteyrand P, Ortonne JP, et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinatc. Br J Dermatol 1991;125:456-9.
125. Tousignant J, Raymond GP, Light MJ. Treatment of cutaneous T-cell lymphoma with the arotinoid Ro 13-6298. J Am Acad Dermatol 1987;16:167-71.
126. Bunn PA, Foon KA, Ihde DC, Longod L, Eddy E, Winkler CF, et al. Recombinant leukocyte A Interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984;101:484-7.
127. Bunn PA, Ihde DC, Foon KA. The role of recombinant Interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986;57:1689-95.
128. Bunn PA, Ihde DC, Foon KA. Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphomas. Int J Cancer 1987;(suppl. I): 9-13.
129. Kohn EC, Steis RG, Sausville EA, Veach SR, Stocker JL, Phelps R, et al. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sezary syndrome. J Clin Oncol 1990;8:155-60.
130. Tura S, Mazza P, Zlnzani PL, Ghetti PL, Poletti G, Gherlinzoni F, et al. Alpha recombinant interferon in the treatment of mycosis fungoides. Haematologica 1987;72:337-40.
131. Dreno B, Godefroy WY, Fleischmann M, Bureau B, Litoux. Low-dose recombinant intcrferon-alpha in the treatment of cutaneous T-cell lymphomas. Br J Dermatol 1989;121:543-4.
132. Lang MH, Altmeyer P, Lodemann E, Holzmann H. Alpha interferon in the therapy of cutaneous T-cell lymphomas. Z Hautkr 1986;61:599-608.
133. Vonderheid EC, Thompson R, Smiles KA, Lattanand A. Recombinant interferon alpha-2b in plaque-phase mycosis fungoides. Arch Dermatol 1987;123:757-63.
134. Thestrup-Pedersen K, Hammer R, Kaltoft K, Sogaards H, Zachariae H. Treatment of mycosis fungoides with recombinant interferon - alpha-2a alone and in combination with etretinate. Br J Dermatol 1988;118:811-8.
135. Estrach AE, Marti R, Lecha M, Mascaro JM. Treatment of cutaneous T-cell lymphoma with recombinant alfa 2B interferon. International Dermatology Symposium on interferons and related cytokines: basic research and applied therapy. Berlin October 11-14, 1989. (Abstract). J Invest Dermatol 1989;93:549.
136. Nicolas JF, Balblanc JC, Frappaz A, Chouvet B, Delcombel M, Thivolet J. Treatment of cutaneous T cell lymphoma with intermediate doses of interferon 2a, Dermatologica 1989;179:34-7.
137. Olsen EA, Rosen ST, Vollmer RT, Variakojis D, Roenigk HH, Diab N. Zeffren J. Interferon alfa-2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989;20:395-407.
138. Bunn PA, Norris DA. Therapeutic role of interferons and monoclonal antibodies in cutaneous T-ccll lymphomas. J Invest Dermatol 1990;95 (suppl.): 210S-212S.
139. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1089-1107.
140. Jumbou O, Dreno B, Bureau B, Celericr PH, Mansat E, Litoux P. Interféron alpha et lymphome cutané T: étude sur le suivi au long cours de 61 patients. Communication Journées Dermatologiques de Paris, 6-9 décembre 1994 (Abstract). Ann Dermatol Vénéréol 1994;122:S27.
141. Wolff JM, Zitelli JA, Rabin BS, Smiles KA, Abell E. Intralesional interferon in the treatment of early mycosis fungoides. J Am Acad Dermatol 1985;13:604-12.
142. Knobler RM, Trautinger F, Radaszkiewicz T, Kokoschka EM, Micksche M. Treatment of cutaneous T-cell lymphoma with a combination of low-dose interferon alpha-2b and retinoids. J Am Acad Dermatol 1991;24:247-52.
143. Braathen LS, McFadden N. Successful treatment of mycosis fungoides with the combination of etretinate and human recombinant interferon alpha-2a. J Dermatol Treatment 1989;7:29-32.
144. Altomare GF, Capella GL, Pigatto PD, Finzi AF. Intramuscular low dose alpha-2b interferon and etretinate for the treatment of mycosis fungoides. Int J Dermatol 1993;32:138-41.
145. Zachariae H, Thestrup-Pedcrsen K. Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990;95:206s-208s.
146. Kuzel TM, Gilyon KG, Springer E. Variakojis D, Paul K, Bunn PA, et al. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990;82:203-7.
147. Roenigk HH, Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990;95:198s-205s.
148. Otte HG, Herges A, Stadler R. Kombinationstherapie mit Interferon ulfa-2a und PUVA bei kutanen T-Zell-Lymphomen. Hautarzt 1992;43:695-9.
149. Kuzel TM, Roenigk HH, Samuelson E, Hemnann JJ, Hurria A, Rademaker AW, Rosen ST. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 1995;13:257-63.
150. Stadler R, Otte HG. Combination therapy of cutaneous T-cell lymphoma with interferon alpha 2a and photochemotherapy. Recent Res Cancer Res 1995;139:391-401.
151. Foss F, Ihde DC, Linnoila IR, Fischmann AB, Schechter GP, et al. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sćzary syndrome. J Clin Oncol 1994;12:2051-9.
152. Kaplan EH, Rosen ST, Norris DB, Roenigk HH, Saks SR, Bunn PA. Phase II study of recombinant interferon gamma for treatment of cutaneous T-cell lymphoma. Natl Cancer Instit 1990;82:208-12.
153. Zinzani PL, Mazza P, Tura S. Beta interferon in the treatment of mycosis fungoides (MF). (Abstract). International Symposium on cutaneous Lymphoma, Copenhagen, Denmark. 28-30 October 1988.
154. Edelson RL, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987;316:297-303.
155. Lim HW, Edelson RL. Photopheresis for the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1117-26.
156. Nagatani T, Matsuzaki T, Kim S, Baba N, Osawa J, Sigiyama A, et al. Treatment of cutaneous T-cell lymphoma (CTCL) with extracorporeal photochemotherapy. Preliminary report. J Dermatol 1990;17:737-45.
157. Rook AH, Cohen JH, Lessin SR, Vowels BR. Therapeutic applications of photopheresis. Dermatol Clin 1993;11:339-47.
158. Collnick HPM, Owssianowski M, Ramaker J, Chun SC, Orfanos CE. Extracorporeal photopheresis. A new approach for the treatment of cutaneous T cell lymphomas. Recent Res Cancer Res 1995;139:409-15.
159. Heald P, Rook A, Perez M, Wintroub B, Knohler R, Jegasothy B, et al. Treatment of crythrodermic cutaneous t-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992;27:427-33.
160. Heald PW, Percz M, Christensen I, Dobbs N, McKiernan G, Edelson R. Photophorcsis therapy of cutaneous T-cell lymphoma: the Yale- New Haven hospital experience. Yale J Biol Med 1989;62:629-38.
161. Duvic M, Hagemeister F, Nester J. Accelerated delivery of extracorporeal photophoresis in patients with cutaneous T cell lymphoma (CTCL). ESDR-JSID-SID Tricontinental meeting. Washington. D.C. April 26-30, 1989. (Abstracts) J Invest Dermatol 1989;92:423.
162. Armus S, Keyes B, Cahill C, Berger C, Crater D, Scarborough D, Klainer A. et al. Photophoresis for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1990;23:898-902.
163. Oziemski MA, Rockman SP, Marks DI, Green MD, Varigos GA, Fox RM. Hxtracorporeal photochemotherapy in the treatment of cutaneous T-cell lymphoma. Complexity of objective evaluation. Int J Dermatol 1991;30:814-7.
164. Zic J, Arzubiaga C, Salhany KE, Parker RA, Wilson D, Stricklin GP, et al. Extracorporeal photophoresis for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1992;27:729-36.
165. Koh HK, Davis BE, Meola T, Lim HW. Extracorporeal photopheresis for the treatment of 34 patients with cutaneous T cell lymphoma (CTCL). The 1994 Annual meeting of the Society for Investigative dermatology. Baltimore, April 27-30, 1994. (Abstract) J Invest Dermatol 1994;102:567.
166. Fimiani M, Rubegni P, D'Asceno G, Andrcassi L. Extracorporcal photochemotherapy in the early treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1994;31:828-9.
167. Heald P, Knobler R, Laroche L. Photoinactivated lymphocyte therapy of cutaneous T-cell lymphoma. Dermatol Clin 1994;12:443-9.
168. Farber EM, Zackheim HS, McClintock RP, Cox AJ Jr. Treatment of mycosis fungoides with various strengths of fluorocinolone acetonide cream. Arch Dermatol 1968;97:165-72.
169. Pineda AA, Winkelmann RK. Leukapheresis in the treatment of Sézary syndrome. J Am Acad Dermatol 1981;5:544-9.
170. Edelson R, Facktor M, Andrews A, Lutzner M, Schein P. Successful management of the Sénary syndrome. Mobilization and removal of extravascular neoplastic T cells by leukapheresis. N Engl J Med 1974;291:293-4.
171. Bcnchiki O, Zeitoun CH, Bagot M, Wechler J, Vaillant L, Joly P, Revuz J. Syndrome de Sézary traité par cytaphérèses. Résultats à court et à long terme. Ann Dermatol Vénéréol 1996;123:247-50.
172. Cooper DL, Braverman IM, Sarris AH, Durivage HJ, Suidman BH, Davis CA, Hait WN. Cyclosporine treatment of refractory T-cell lymphomas. Cancer 1993;71:2335-41.
173. Kreis W, Budman DR, Shapiro PE. Cyclosporin A (cyclosporine) in the treatment of cutaneous T cell lymphoma (mycosis fungoides). J Am Acad Dermatol 1988;18:1138-9.
174. Street ML, Muller SA, Pittelkow MR. Cyclosporine in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1990;23:1084-9.
175. Catteral MD, Addis BJ, Smith JL, Coode PE. Sézary syndrome: transformation to high-grade T-cell lymphoma after treatment with cyclosporine. Clin Exp Dermatol 1983;8:159-69.
176. Bertram JH, Gill PS, Levine AM, Boquiren D, Hoffman FM, Meyer P, Mitchell MS. Monoclonal antibody T101 in T cell malignancies: a clinical, pharmacokinetic and immunologic correlation. Blood 1986:68:752-61.
177. Lemaistre CF, Rosen S, Frankel A, Kornfeld S, Saria E, Meneghetti C, et al. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 1991;78:1173-82.
178. Knox SJ, Levy R, Hodgkinson S, Bell R, Brown S, Wood GS. et al. Observations on the effect of ehimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood 1991;77:20-30.
179. Edelson RL, Raafat J, Berger CL, Grossman M, Troyer C, Hardy M. Antithymocyte globulin in the management of cutaneous T-cell lymphoma. Cancer Treat Rep 1979;63:675-80.
180. Bernengo MG, Appino A, Bertero M, Novelli R, Fierro MT, Doveil GC, Lisa F. Thymopoietin in Sezary syndrome. J Natl Cancer Inst 1992;84:1341-6.
181. Przybilla B, Burg G, Schmoeckel C, Braun-Falco O. Treatment of cutaneous T-cell lymphomas with TP-S. Acta Dermatol Venereol (Stockh) 1983;63:524-9.
182. Bernengo MG, Doveil GC, Meregalli M, Appino A, Massobrio R. Immunomodulation and Sézary syndrome: experience with thymopentin (TP-5). Br J Dermatol 1988;119:207-21.
183. Foss FM, Borkowski TA, Gilliom M, Stetler-Stevenson MA, Jaffe ES, Figg WD, et al. Chimeric fusion protein toxin DAB 4861L-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 1994;84:1765-74.
184. Gisselbrecht C, Maraninchi D, Pico JL, Milpied N, Coiffier B, Divine M, et al. Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 1994;85:2081-5.
185. Marolleau JP, Baccard M, Flageul B, Rybojad M, Laroche L, Verola O, et al. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 1995;131:574-9.
186. Hesketh P, Caguioa P, Koh H, Dewey H, Facada A, McCaffrey R, et al. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J Clin Oncol 1993;11:1682-90.
187. Wolf P, Fink-Puches R, Cerroni L, Kerl H. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol 1994;31:678-80.
188. Boehncke WH, König K, Rück A, Kaufmann R, Sterry W. In vitro and in vivo effects of photodynamic therapy in cutaneous T cell lymphoma. Acta Dermatol Venereol (Stockh) 1994;74:201-5.
189. Shandler SD, Wan W, Whitaker JE, Jones C, Wilson BD, Stoll HL, et al. Topical δ-aminolevulinic acid for photodynamic therapy of cutaneous carcinoma and cutaneous T cell lymphoma. (Abstract). J Invest Dermatol 1993;101:406.
190. Ammann R, Hunziker TH. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol 1995;33:541.
191. Burg G, Klepzig K, Kaudewitz P, Wolf H, Braun-Falco O. Acyclovir in lymphomatoid papulosis and mycosis fungoides. JAMA, 1986;256:214-5.
192. Weiss LM, Wood GS, Hu E, Abel EA, Hoppe RT, Sklar J. Detection of clonal T-cell receptor gene rearrangements in the peripheral blood of patients with mycosis fungoides/Sézary syndrome. J Invest Dermatol 1989;92:601-14.